Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: The impact of comorbidity and demographics on initial choice
Background: Australian clinical guidelines recommend endocrine therapy for all women with hormone-dependent early breast cancer. Guidelines specify tamoxifen as first-line therapy for pre-menopausal women, and tamoxifen or an aromatase inhibitor (AI) for post-menopausal women depending on the risk o...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Public Library of Science
2014
|
| Online Access: | http://hdl.handle.net/20.500.11937/56032 |